Validation of the IL-6 signaling pathway as a target in RA has also been established by the clinical efficacy in multicenter trials of tocilizumab, a humanized anti-IL-6 receptor antibody [16], and in a pilot study of B-E8, a murine anti-IL-6 monoclonal antibody (mAb) [17]. The gene discussed is IL6; the disease is rheumatoid arthritis.